Introduction and objective: Microplastics are widespread environmental contaminants, and their potential impact on human health has attracted increasing scientific attention. Due to their small size and physicochemical properties, they may enter the human body mainly through ingestion and...
5 August 2024 in Journal of Pre-Clinical and Clinical Research
Introduction: Brain abscess is accumulation of pus in brain parenchyma. Predisposing factors include head trauma and spreading the inflammatory process from remote locations or from surroundings. The most common location is the frontal lobe. Frequent pathogens that cause paediatric BA are S....
22 December 2025 in Current Issues in Pharmacy and Medical Sciences
Oncology patients face numerous challenges resulting both from their underlying disease and from the adverse effects of anticancer treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is among the most serious complications associated with chemotherapy. The sensory and motor disturbances observed in the course of CIPN are often progressive and may be irreversible, while severe and chronic pain leads to a substantial reduction in patients’ quality of life (QoL). This narrative review summarizes currently available topical treatment options for CIPN, focusing on substances that have shown potential clinical benefit. The pathogenesis of CIPN remains incompletely understood, and existing treatment strategies are frequently insufficient or associated with significant adverse effects. Consequently, both the prevention and management of CIPN remain important challenges in contemporary medicine. Recently, increasing attention has been directed toward topically administered agents, including formulations based on phenytoin, lidocaine, amitriptyline, capsaicin, cannabinoids, duloxetine, ketamine, and baclofen. These therapies may alleviate neuropathic symptoms and improve QoL without the systemic complications commonly associated with oral or intravenous pharmacotherapy. The use of topical medications may also allow for a reduction in systemic analgesic doses and is often favored due to their more favorable safety profile. Therefore, topical agents should be considered promising therapeutic options aimed at minimizing systemic side effects and optimizing the current pharmacological management of patients with CIPN.
BackgroundAutism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by deficits in social communication and restricted, repetitive behaviors. Its growing prevalence and functional burden have increased interest in non-pharmacological interventions, particularly physical activity and sport-based programs, as potential strategies to improve physical and neurobehavioral outcomes in pediatric populations. AimThis narrative review aimed to summarize current evidence on the effects of physical activity and exercise interventions on motor, cognitive, behavioral, and psychosocial outcomes in children and adolescents with ASD. Material and methodsA narrative literature review was conducted using peer-reviewed studies on exercise-based interventions in pediatric ASD populations. Included were systematic reviews, meta-analyses, randomized controlled trials, and experimental studies assessing outcomes such as motor skills, executive functioning, social interaction, sleep, and behavioral regulation. ResultsEvidence indicates that structured physical activity may positively affect multiple domains in children with ASD. Exercise interventions were associated with improvements in motor skills, executive functions, and social abilities, along with reductions in behavioral problems and anxiety. Some studies also reported improved sleep and overall well-being. However, significant heterogeneity in intervention types, duration, and outcome measures was noted. ConclusionsPhysical activity is a valuable complementary element of multidisciplinary ASD management, supporting both physical health and neurobehavioral functioning. Further well-designed studies with standardized protocols and long-term follow-up are needed to determine optimal intervention strategies and their sustained effects.
Atopic dermatitis (AD) is a chronic, inflammatory skin disease that often begins in early childhood and significantly affects the quality of life of patients and their families. Conventional treatments include emollients, corticosteroids, and calcineurin inhibitors; however, these are often insufficient in moderate-to-severe cases. In recent years, novel targeted therapies, including biologics and Janus kinase (JAK) inhibitors, have shown promising clinical results in pediatric patients. Dupilumab and tralokinumab, monoclonal antibodies, have demonstrated significant improvement in AD symptoms, including reduction of pruritus and inflammation. JAK inhibitors, such as upadacitinib, abrocitinib, and baricitinib, modulate cytokine pathways involved in AD pathogenesis, leading to rapid and sustained improvement of skin lesions. These novel therapies exhibit favorable safety profiles and enable personalized approaches. This article reviews current evidence on the efficacy and safety of dupilumab, tralokinumab, and JAK inhibitors in the pediatric population, highlighting their role in modern AD management.
12 May 2025 in Journal of Pre-Clinical and Clinical Research
Autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are difficult to recognize and diagnose. Symptoms are non-specific, appear suddenly, and may be related to a prior Group A beta-haemolytic streptococcal infection. Limited research complicates treatment. The...